TNO as an independent research and technology institute is supporting the biotech and pharmaceutical industry via innovative pre- and clinical platforms and tools accelerating and de-risking drug development. We have disease models for NASH, Fibrosis and Diabetes, innovative toxicology capabilities like target safety assessment and in vitro/ex vivo platforms to predict pharmacokinetics and metabolism. Besides we are are the only global biomedical facility offering u-dosing/tracer AMS studies generating AbsBA and MIST/mass balance data as early as phase 1.